1. An isolated composition comprising an anti-IL-13 antibody or antigen binding portion thereof, where, if administered to an individual at a dose of approximately 0.3 mg / kg, the antibody or antigen binding portion thereof is capable of showing: (a) the area under the curve ( AUC) equal to from about 1500 to about 2700 mcg / ml； (b) a distribution volume of from about 65 to 125 ml / kg； (c) a peak concentration (C) of from about 5 to about 8 mcg / ml； and (d) an excretion rate of from about 0.1 to about 0.2 ml / h / kg. 2. An isolated composition comprising an anti-IL-13 antibody or antigen binding part thereof, where, if administered to an individual at a dose of approximately 3 mg / kg, the antibody or antigen binding part thereof is capable of showing: (a) an area under the curve (AUC) of from about 21,000 to about 33,500 μg / ml； (b) a distribution volume of from about 55 to about 100 ml / kg； (c) a peak concentration (C) of from about 55 to about 90 μg / ml； and (d) an excretion rate of from about 0.08 to about 0.15 ml / h / kg. 3. An isolated composition comprising an anti-IL-13 antibody or antigen binding portion thereof, where, if administered to an individual at a dose of about 10 mg / kg, the antibody or antigen binding portion thereof is capable of showing: (a) area under the curve (AUC), equal to from about 75 to about 100 μg / ml； (b) a distribution volume of from about 90 to about 130 ml / kg； (c) a peak concentration (C) of from about 185 to about 250 μg / ml； and (d) the rate of excretion,1. Выделенная композиция, содержащая антитело против IL-13 или его антигенсвязывающую часть, где, если проводить внутривенное введение индивиду в дозе, равной приблизительно 0,3 мг/кг, антитело или его антигенсвязывающая часть способны демонстрировать:(a) площадь под кривой (AUC), равную от приблизительно 1500 до приблизительно 2700 мкгч/мл；(b) объем распределения, равный от приблизительно 65 до 125 мл/кг；(c) пиковую концентрацию (C), равную от приблизительно 5 до
